VellemaJVan de MunckhofACoutinhoJM.Cerebral venous thrombosis: current management, recent advances and future directions. Int J Stroke2025; 20: 1177–1187.
2.
ZhangXFangKZhangY, et al. Cerebral venous thrombosis during pregnancy and postpartum: a systematic review and meta-analysis. Int J Stroke2025; 20: 1188–1200.
3.
CoutinhoJMVan de MunckhofAAguiar de SousaD, et al. Reducing the global burden of cerebral venous thrombosis: an international research agenda. Int J Stroke2024; 19: 599–610.
4.
MaHGuYBianT, et al. Dabigatran etexilate versus warfarin in cerebral venous thrombosis in Chinese patients (CHOICE-CVT): an open-label, randomized controlled trial. Int J Stroke2024; 19: 635–644.
5.
TaveiraMCAaronSFerreiraJM, et al. Timing of starting anticoagulation following decompressive surgery for cerebral vein and sinus thrombosis: an observational study. Int J Stroke2025, 20: 1225–1234.
6.
AaronSFerreiraJMCoutinhoJM, et al.; DECOMPRESS2 Study Group. Outcomes of decompressive surgery for patients with severe cerebral venous thrombosis: DECOMPRESS2 observational study. Stroke2024; 55: 1218–1226.
7.
BrakelBARebchukADOspelJ, et al. International practice patterns and perspectives on endovascular therapy for the treatment of cerebral venous thrombosis. Int J Stroke2025; 20: 319–327.
8.
Parry-JonesARKrishnamurthiRZiaiWC, et al. World Stroke Organization (WSO): global intracerebral hemorrhage factsheet 2025. Int J Stroke2025; 20: 145–150.
9.
SelimMFosterLDMoyCS, et al. I-DEF Investigators. Deferoxamine mesylate in patients with intracerebral haemorrhage (I-def): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol2019; 18: 428–438.
10.
FosterLRobinsonLYeattsSD, et al.; I-DEF Investigators. Effect of deferoxamine on trajectory of recovery after intracerebral hemorrhage: a post hoc analysis of the i-DEF trial. Stroke2022; 53: 2204–2210.
11.
PolymerisAALioutasV-AFosterLD, et al. Early neurological improvement with deferoxamine after intracerebral hemorrhage: a post hoc analysis of the i-DEF trial. Int J Stroke2025, 20: 1235–1245.
12.
NewmanCBPreissDTobertJA.Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol2019; 39: e38–e81.
13.
HuXWangZLiuJ, et al. Statin use is associated with reduced risk of incident intracerebral hemorrhage: a prospective population-based cohort study. Int J Stroke2025, 20: 1280–1289.
14.
SylajaPNambiarVNarayanS, et al. Ayurvedic treatment in the rehabilitation of ischemic stroke patients in India: a randomized controlled trial (RESTORE). Int J Stroke2025, 20: 1214–1224.
15.
AnXWangBGeX, et al. Effectiveness of external ventricular drainage versus lumbar drainage in aneurysmal subarachnoid hemorrhage: a propensity-matched multicenter study. Int J Stroke2025; 20: 1071–1080.
16.
MusmarBAbdalrazeqHRoyJM, et al. Outcomes of external ventricular drainage and lumbar drainage in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Int J Stroke2025, 20: 1201–1213.
17.
MokVCTCaiYMarkusHS.Vascular cognitive impairment and dementia: mechanisms, treatment, and future directions. Int J Stroke2024; 19: 838–856.
18.
WongGKLamSWNgaiK, et al. Cognitive domain deficits in patients with aneurysmal subarachnoid haemorrhage at 1 year. J Neurol Neurosurg Psychiatry2013; 84: 1054–1058.
